Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
@icrlordlab.bsky.social
Two heads are better than one ! Joint lab heads. Director & Dept Director Breast Cancer Now Research Centre at @icrlondon.bsky.social. Precision Oncology, HRD, PARPi, synthetic lethality, breast & other cancers. Trying to do some damage.
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
Really pleased to have presented work on targeting GPR89 in breast cancer with @ricoferro.bsky.social from the Tutt and Lord labs as part of the ICRs Centre for Target Validation @icrlordlab.bsky.social at #Targets2025 in Boston @icr.ac.uk @breastcancernow.bsky.social
October 25, 2025 at 8:02 PM
Really pleased to have presented work on targeting GPR89 in breast cancer with @ricoferro.bsky.social from the Tutt and Lord labs as part of the ICRs Centre for Target Validation @icrlordlab.bsky.social at #Targets2025 in Boston @icr.ac.uk @breastcancernow.bsky.social
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
Ever wondered what S-phase tastes like? 3 lucky presenter prize winners will find out (+Amazon voucher!) at #ACDTM25. You can still register for this fantastic Melbourne meeting Oct 20-22. Official 10 year old taste tester: "lemon excision repair" is the best flavour www.australiancellcycle.org
October 13, 2025 at 2:25 AM
Ever wondered what S-phase tastes like? 3 lucky presenter prize winners will find out (+Amazon voucher!) at #ACDTM25. You can still register for this fantastic Melbourne meeting Oct 20-22. Official 10 year old taste tester: "lemon excision repair" is the best flavour www.australiancellcycle.org
We're hiring ! Specifically....we are seeking to appoint a creative and motivated Postdoctoral Training Fellow to study how drug resistance emerges in homologous recombination defective (HRD) breast cancers and how this could be targeted. jobs.icr.ac.uk/vacancies/13...
PDTF - Homologous Recombination Defective Cancers ( Profs Chris Lord and Andrew Tutt) in Chelsea | The Institute of Cancer Research
View details and apply for this PDTF - Homologous Recombination Defective Cancers ( Profs Chris Lord and Andrew Tutt) vacancy in Chelsea .
Salary: Dependent on relevant Postdoctoral exp...
jobs.icr.ac.uk
September 19, 2025 at 7:38 AM
We're hiring ! Specifically....we are seeking to appoint a creative and motivated Postdoctoral Training Fellow to study how drug resistance emerges in homologous recombination defective (HRD) breast cancers and how this could be targeted. jobs.icr.ac.uk/vacancies/13...
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
RFK Jr. taps his top deputy, Jim O’Neill, to be the new CDC director. Both men appear to wear skinny ties from Otaa. Otaa's ties are made in China from microfiber, a kind of plastic that, under the right conditions, can migrate to your balls.
August 29, 2025 at 6:51 PM
RFK Jr. taps his top deputy, Jim O’Neill, to be the new CDC director. Both men appear to wear skinny ties from Otaa. Otaa's ties are made in China from microfiber, a kind of plastic that, under the right conditions, can migrate to your balls.
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
Thrilled to share our latest work, just published in @nature.com ⬇
www.nature.com/articles/s41...
We discovered that PARP inhibitors 💊 trigger histone eviction from the chromatin and this creates a hidden vulnerability in PARPi resistant tumors.
🧵 (1/8)
www.nature.com/articles/s41...
We discovered that PARP inhibitors 💊 trigger histone eviction from the chromatin and this creates a hidden vulnerability in PARPi resistant tumors.
🧵 (1/8)
NASP modulates histone turnover to drive PARP inhibitor resistance - Nature
PARP inhibitor treatment triggers histone release from the chromatin in cancer cells; consequently, targeting the histone chaperone NASP renders cells vulnerable to PARP inhibition.
www.nature.com
August 13, 2025 at 3:44 PM
Thrilled to share our latest work, just published in @nature.com ⬇
www.nature.com/articles/s41...
We discovered that PARP inhibitors 💊 trigger histone eviction from the chromatin and this creates a hidden vulnerability in PARPi resistant tumors.
🧵 (1/8)
www.nature.com/articles/s41...
We discovered that PARP inhibitors 💊 trigger histone eviction from the chromatin and this creates a hidden vulnerability in PARPi resistant tumors.
🧵 (1/8)
With super Roman Chabanon and Sophie Postal Vinay, we show that inhibition of RNA editor ADAR1 causes a new form of BRCA synthetic lethality>autocrine inferferon poisoning. Relevant for ADAR1 drug discovery. Could provide a mechanistically different approach than PARPi. rdcu.be/eyo6t
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers
Nature Communications - The RNA editing enzyme ADAR1 blocks interferon responses triggered by cytosolic RNA sensors, and has been proposed as a potential target in immuno-oncology. Here, the...
rdcu.be
July 30, 2025 at 8:32 AM
With super Roman Chabanon and Sophie Postal Vinay, we show that inhibition of RNA editor ADAR1 causes a new form of BRCA synthetic lethality>autocrine inferferon poisoning. Relevant for ADAR1 drug discovery. Could provide a mechanistically different approach than PARPi. rdcu.be/eyo6t
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers
Nature Communications - The RNA editing enzyme ADAR1 blocks interferon responses triggered by cytosolic RNA sensors, and has been proposed as a potential target in immuno-oncology. Here, the...
rdcu.be
July 30, 2025 at 8:29 AM
With super Roman Chabanon and Sophie Postal Vinay, we show that inhibition of RNA editor ADAR1 causes a new form of BRCA synthetic lethality>autocrine inferferon poisoning. Relevant for ADAR1 drug discovery. Could provide a mechanistically different approach than PARPi. rdcu.be/eyo6t
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
Academic writing is a craft. ✍️
You’re not born knowing how to write great papers, succinct emails, or convincing proposals. You get better by doing it badly, then better, then well.
Your writing is the first thing people see before they meet you. Make it count.
You’re not born knowing how to write great papers, succinct emails, or convincing proposals. You get better by doing it badly, then better, then well.
Your writing is the first thing people see before they meet you. Make it count.
July 9, 2025 at 3:45 PM
Academic writing is a craft. ✍️
You’re not born knowing how to write great papers, succinct emails, or convincing proposals. You get better by doing it badly, then better, then well.
Your writing is the first thing people see before they meet you. Make it count.
You’re not born knowing how to write great papers, succinct emails, or convincing proposals. You get better by doing it badly, then better, then well.
Your writing is the first thing people see before they meet you. Make it count.
This is fascinating:
This is cool. An archaeal species with no metabolic genes. Just replicative genes (ribosomes, messenger and transfer RNAs). 238kb genome.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
June 27, 2025 at 8:19 AM
This is fascinating:
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
Incredibly humbled and honoured to have been awarded the 2025 Research Prize from @thelisterinstitute.bsky.social. ❤️
🧬 We’re harnessing high-resolution molecular profiling + AI to uncover how cancer disables the immune system and find ways of restoring it. @icr.ac.uk
#bcsm #ai #CancerResearch
🧬 We’re harnessing high-resolution molecular profiling + AI to uncover how cancer disables the immune system and find ways of restoring it. @icr.ac.uk
#bcsm #ai #CancerResearch
We are very proud to introduce our brand new 2025 #ListerFellows! This year there are eight Prize recipients. lister-institute.org.uk/a-warm-welco...
June 19, 2025 at 12:03 PM
Incredibly humbled and honoured to have been awarded the 2025 Research Prize from @thelisterinstitute.bsky.social. ❤️
🧬 We’re harnessing high-resolution molecular profiling + AI to uncover how cancer disables the immune system and find ways of restoring it. @icr.ac.uk
#bcsm #ai #CancerResearch
🧬 We’re harnessing high-resolution molecular profiling + AI to uncover how cancer disables the immune system and find ways of restoring it. @icr.ac.uk
#bcsm #ai #CancerResearch
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
🧬 Excited to announce the 2nd Euro Cancer DepMap Symposium bringing together leading minds in functional genomics, cancer vulnerabilities, AI, CRISPR and anti-cancer target discovery.📍Join us in Milan for cutting-edge science, open discussion & collaboration. #EuroDepMap #CancerResearch #CRISPR
June 11, 2025 at 3:00 PM
🧬 Excited to announce the 2nd Euro Cancer DepMap Symposium bringing together leading minds in functional genomics, cancer vulnerabilities, AI, CRISPR and anti-cancer target discovery.📍Join us in Milan for cutting-edge science, open discussion & collaboration. #EuroDepMap #CancerResearch #CRISPR
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
Following the success of the first European Cancer Dependency Map Symposium in 2023, we are excited to announce the 2nd edition, to be held at Human Technopole on the 20th November 2025. Registration and Poster submission now open!
humantechnopole.it/en/trainings...
youtu.be/x2erCuovGvc
#EuroDepMap
humantechnopole.it/en/trainings...
youtu.be/x2erCuovGvc
#EuroDepMap
1st European Cancer Dependency Map Symposium
YouTube video by Human Technopole
youtu.be
June 11, 2025 at 4:06 PM
Following the success of the first European Cancer Dependency Map Symposium in 2023, we are excited to announce the 2nd edition, to be held at Human Technopole on the 20th November 2025. Registration and Poster submission now open!
humantechnopole.it/en/trainings...
youtu.be/x2erCuovGvc
#EuroDepMap
humantechnopole.it/en/trainings...
youtu.be/x2erCuovGvc
#EuroDepMap
Loving “pertomics”. Going to push the term “buffomics” too.
congrats to @maxbillmann.bsky.social on making 'pertomics' an official published term www.embopress.org/doi/full/10....
Who controls the tariffs of a human cell? | Molecular Systems Biology
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
www.embopress.org
May 14, 2025 at 8:39 AM
Loving “pertomics”. Going to push the term “buffomics” too.
We're looking for a Scientific Operations Project Manager
to join us at ICR, London. Role is aimed at establishing new funding streams, collaborations with biotech. and pharma and managing collaborations with other academic groups. jobs.icr.ac.uk/vacancies/11...
to join us at ICR, London. Role is aimed at establishing new funding streams, collaborations with biotech. and pharma and managing collaborations with other academic groups. jobs.icr.ac.uk/vacancies/11...
Scientific Operations Project Manager in Chelsea | The Institute of Cancer Research
View details and apply for this Scientific Operations Project Manager vacancy in Chelsea .
Salary : Commencement on the salary range is subject to comparable skills and experience. Future p...
jobs.icr.ac.uk
April 25, 2025 at 9:49 PM
We're looking for a Scientific Operations Project Manager
to join us at ICR, London. Role is aimed at establishing new funding streams, collaborations with biotech. and pharma and managing collaborations with other academic groups. jobs.icr.ac.uk/vacancies/11...
to join us at ICR, London. Role is aimed at establishing new funding streams, collaborations with biotech. and pharma and managing collaborations with other academic groups. jobs.icr.ac.uk/vacancies/11...
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
The OptiTROP-Breast01 phase 3 trial evaluated sacituzumab tirumotecan (sac-TMT) versus chemotherapy in patients with heavily pretreated, locally recurrent or metastatic triple-negative #BreastCancer
www.nature.com/articles/s41...
✅Sac-TMT significantly improved progression-free survival PFS
www.nature.com/articles/s41...
✅Sac-TMT significantly improved progression-free survival PFS
April 11, 2025 at 12:42 PM
The OptiTROP-Breast01 phase 3 trial evaluated sacituzumab tirumotecan (sac-TMT) versus chemotherapy in patients with heavily pretreated, locally recurrent or metastatic triple-negative #BreastCancer
www.nature.com/articles/s41...
✅Sac-TMT significantly improved progression-free survival PFS
www.nature.com/articles/s41...
✅Sac-TMT significantly improved progression-free survival PFS
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
this week 20 years ago, Nature published two seminal papers showing for the first time that BRCA-mutant cells were selectively sensitive to PARP inhibitors, paving the way for clinical trials and approval of PARP inhibitors for patients with BRCA-mutant ovarian and breast cancers, and beyond.
April 15, 2025 at 12:07 PM
this week 20 years ago, Nature published two seminal papers showing for the first time that BRCA-mutant cells were selectively sensitive to PARP inhibitors, paving the way for clinical trials and approval of PARP inhibitors for patients with BRCA-mutant ovarian and breast cancers, and beyond.
Interested in starting your cancer research career in London ?We're looking for a Scientific Officer to support our work on synthetic lethality in triple negative and BRCA1/2 mutant cancers. Ideal job for a new graduate who wants to kick start their research career. jobs.icr.ac.uk/vacancies/12...
Scientific Officer - Target Validation and DNA Damage Response Group (Prof Andrew Tutt) in Chelsea | The Institute of Cancer Research
View details and apply for this Scientific Officer - Target Validation and DNA Damage Response Group (Prof Andrew Tutt) vacancy in Chelsea .
Salary : Commencement on the salary range is s...
jobs.icr.ac.uk
April 14, 2025 at 7:51 AM
Interested in starting your cancer research career in London ?We're looking for a Scientific Officer to support our work on synthetic lethality in triple negative and BRCA1/2 mutant cancers. Ideal job for a new graduate who wants to kick start their research career. jobs.icr.ac.uk/vacancies/12...
And Elvis 75 the best single never released
April 11, 2025 at 10:10 PM
And Elvis 75 the best single never released
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
PAPER OUT!! 🥳🎉💃🏻🕺🏻💃🏻🕺🏻
A redefined InDel taxonomy provides insights into mutational signatures @NatureGenet
Brainchild of the amazing #GeneKoh
(Sir Jeffrey Cheah ECR)
Tweetorial below!! 👇
1/n
www.nature.com/articles/s41...
A redefined InDel taxonomy provides insights into mutational signatures @NatureGenet
Brainchild of the amazing #GeneKoh
(Sir Jeffrey Cheah ECR)
Tweetorial below!! 👇
1/n
www.nature.com/articles/s41...
A redefined InDel taxonomy provides insights into mutational signatures - Nature Genetics
This paper describes a framework for classifying small insertions and deletions from genomic data and applies it to a large dataset comprising seven tumor types. The analysis highlights new insertion ...
www.nature.com
April 10, 2025 at 4:48 PM
PAPER OUT!! 🥳🎉💃🏻🕺🏻💃🏻🕺🏻
A redefined InDel taxonomy provides insights into mutational signatures @NatureGenet
Brainchild of the amazing #GeneKoh
(Sir Jeffrey Cheah ECR)
Tweetorial below!! 👇
1/n
www.nature.com/articles/s41...
A redefined InDel taxonomy provides insights into mutational signatures @NatureGenet
Brainchild of the amazing #GeneKoh
(Sir Jeffrey Cheah ECR)
Tweetorial below!! 👇
1/n
www.nature.com/articles/s41...
www.bbc.co.uk/news/article.... Excellent news for breast cancer patients, based on great work from ICR scientists including our own Nick Turner.
New pill can slow progression of incurable breast cancer
Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
www.bbc.co.uk
April 11, 2025 at 5:35 AM
www.bbc.co.uk/news/article.... Excellent news for breast cancer patients, based on great work from ICR scientists including our own Nick Turner.
Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
A must for all DNA repair aficionados!
Egmond DNA Repair Meeting → April 19–24, 2026 🇳🇱
✔️ Confirmed top speakers
✔️ Ample opportunities for talks & posters
Don’t miss it: dnarepairmeeting-egmond2026.com
Egmond DNA Repair Meeting → April 19–24, 2026 🇳🇱
✔️ Confirmed top speakers
✔️ Ample opportunities for talks & posters
Don’t miss it: dnarepairmeeting-egmond2026.com
April 9, 2025 at 8:05 AM
A must for all DNA repair aficionados!
Egmond DNA Repair Meeting → April 19–24, 2026 🇳🇱
✔️ Confirmed top speakers
✔️ Ample opportunities for talks & posters
Don’t miss it: dnarepairmeeting-egmond2026.com
Egmond DNA Repair Meeting → April 19–24, 2026 🇳🇱
✔️ Confirmed top speakers
✔️ Ample opportunities for talks & posters
Don’t miss it: dnarepairmeeting-egmond2026.com
We had the most fantastic joint lab retreat with our friends @josjonkers.bsky.social and Sabine Linn and their super smart colleagues @nkinl.bsky.social. The start of a lot of collaborative work targeting HRD and ILC.
April 4, 2025 at 4:51 PM
We had the most fantastic joint lab retreat with our friends @josjonkers.bsky.social and Sabine Linn and their super smart colleagues @nkinl.bsky.social. The start of a lot of collaborative work targeting HRD and ILC.